来自MSN

Swiss Re Study: GLP-1 Medications Could Significantly Reduce Mortality by 2045

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Swiss Re AG ( (CH:SREN)) has issued an ...
Insurancenewsnet.com

Swiss Re study: GLP-1 drugs could cut U.S. mortality a staggering 6.4% by 2045

The continued use of GLP-1 weight loss drugs could cut mortality rates by up to 6.4% by 2045, according to new research spearheaded by Swiss Re. Titled "The future of metabolic health and weight loss ...